| Name | Title | Contact Details |
|---|
Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology.
Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).
Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible.
The UroLift System is an FDA Cleared, revolutionary minimally invasive treatment of Benign Prostatic Hyperplasia (BPH) or an enlarged prostate.
Sanofi SA is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the worlds fifth-largest by prescription sales.